Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.59 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.57 |
| ▸ | TYR | P14679 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29998779 | 1.00 | MTNR1A (0.59) | MTNR1AMTNR1BALOX5OR51E2TYR | |
| SCHEMBL8383176 | 0.90 | CYP1A2 (0.51) | TSHRLMNACA1CA2CA12 | |
| SCHEMBL31432851 | 0.89 | CA12 (0.64) | CA1CA2CA12CA9 | |
| SCHEMBL903446 | 0.89 | CA12 (0.64) | CA1CA2CA12CA9 | |
| SCHEMBL15103325 | 0.88 | MTNR1A (0.66) | MTNR1AMTNR1BALOX5OR51E2TYR | |
| SCHEMBL2574214 | 0.86 | CYP1A2 (0.56) | TSHR | |
| SCHEMBL30423117 | 0.86 | MAPT (0.63) | TYRACHETSHRMAPK1LMNA | |
| SCHEMBL233765 | 0.86 | MAPT (0.63) | TYRACHETSHRMAPK1LMNA | |
| SCHEMBL6678480 | 0.86 | CA1 (0.50) | LMNACA1CA2CA12CA9 | |
| SCHEMBL5355912 | 0.86 | CA12 (0.50) | CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4326227-A1 | STABILIZED FORMULATIONS | ModernaTX, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3564233-B1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2023-05-03 | — | — | EP | disclosed |
| EP-4101849-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | Novartis AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| US-20220387428-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20220370616-A1 | STABILIZED FORMULATIONS | ARES CAPITAL CORPORATION, AS AGENT | 2022-11-24 | — | — | US | disclosed |
| WO-2022226277-A1 | STABILIZED FORMULATIONS | MODERNATX, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| US-11229648-B2 | 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2022-01-25 | — | — | US | disclosed |
| EP-2885288-B1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| CN-109942593-B | Total synthesis method of racemic tetrandrine | 浙江金华康恩贝生物制药有限公司 | 2021-08-27 | — | — | CN | disclosed |
| US-20210230155-A1 | PROCESS FOR PREPARATION OF ((3R,11BR)-1,3,4,6,7,11B-HEXAHYDRO-9,10-DI(METHOXY-D3)-3-(2-METHYLPROPYL)-2H-BENZO[A]QUINOLIZIN-2-ONE | HETERO LABS LIMITED (IN) | 2021-07-29 | — | — | US | disclosed |
| US-7855227-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-12-21 | — | — | US | disclosed |
| US-7855227-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-12-21 | — | — | US | disclosed |
| US-7855227-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-12-21 | — | — | US | disclosed |
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. | 2008-12-25 | — | — | US | disclosed |
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. | 2008-12-25 | — | — | US | disclosed |
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. | 2008-12-25 | — | — | US | disclosed |
| EP-1963280-A1 | 2 -PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | Newron Pharmaceuticals S.p.A. (IT) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007071311-A1 | 2 -PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071311-A1 | 2 -PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-28 | — | — | WO | disclosed |
| US-6787670-B1 | SUCH AS N-(4-(CYANOMETHOXY)-3-METHOXYPHENETHYL)-2-(METHOXY-IMINO)-2-(5,6,7,8 -TETRAHYDRO-2-NAPHTHYL)ACETAMIDE; PREVENTING PLANT DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | CACNA1A, CACNA1E, CACNA1I | MTNR1A 334/4885MTNR1B 475/4885ALOX5 2631/4885 |
| US-11229648-B2 | 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, SF3B5, CLN6 | MTNR1A 1651/4885MTNR1B 748/4885ALOX5 2132/4885 |
| US-20220370616-A1 | STABILIZED FORMULATIONS | RNMT, NSUN2, POLN | MTNR1A 3458/4885MTNR1B 3579/4885ALOX5 1621/4885 |
| US-20220387428-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, SF3B5 | MTNR1A 1491/4885MTNR1B 707/4885ALOX5 2350/4885 |
| US-20210230155-A1 | PROCESS FOR PREPARATION OF ((3R,11BR)-1,3,4,6,7,11B-HEXAHYDRO-9,10-DI(METHOXY-D3)-3-(2-METHYLPROPYL)-2H-BENZO[A]QUINOLIZIN-2-ONE | CYP4B1, CYP1B1, UGT1A3 | MTNR1A 89/4885MTNR1B 35/4885ALOX5 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.